LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of ...

EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the ...

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster Vaccine ...

6 About Shingrix (Recombinant Zoster Vaccine or RZV) Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in adults 50 ...